#1 Clinical Trials Search in Europe

Rbp030.2

RBP030.2, also known as BNT211, is an innovative drug currently being studied in clinical trials for patients with advanced solid tumors. This article will provide an overview of the ongoing research, including the drug’s potential benefits, target patient groups, and the trial’s objectives. We’ll explore how this new therapy might offer hope for patients with limited treatment options.

Table of Contents

What is RBP030.2?

RBP030.2 is an investigational treatment being developed by BIONTECH SE for advanced solid tumors. It is also known by its product name BNT211[1]. This treatment is classified as a cell therapy, specifically a type of CAR-T cell therapy. CAR-T stands for Chimeric Antigen Receptor T-cell, which is a form of immunotherapy where a patient’s own immune cells are modified to fight cancer more effectively.

How does RBP030.2 work?

RBP030.2 works by targeting a specific protein called claudin 6 (CLDN6) that is found on some cancer cells[1]. The treatment involves taking T-cells (a type of immune cell) from the patient’s body and genetically modifying them to recognize and attack cells that express CLDN6. These modified cells, called CLDN6 CAR-T cells, are then infused back into the patient’s body to fight the cancer.

In some cases, the treatment may be combined with a CLDN6 RNA-LPX vaccine. This vaccine is designed to further boost the immune response against CLDN6-expressing cancer cells[1].

What conditions does RBP030.2 target?

RBP030.2 is being investigated for the treatment of several types of advanced solid tumors, including:

  • Malignant solid tumors: These are cancers that form solid masses in various organs.
  • Carcinoma of unknown primary: A rare type of cancer where doctors can’t determine where the cancer originally started.
  • Testicular cancer: Cancer that develops in the testicles.
  • Non-small cell lung cancer: A common type of lung cancer[1].

The treatment is specifically designed for patients with tumors that express the CLDN6 protein on at least 50% of their cells[1].

Current Clinical Trial

RBP030.2 is currently being studied in a Phase I/IIa clinical trial. This is a first-in-human study, which means it’s the first time this treatment is being tested in people. The trial aims to evaluate the safety and preliminary effectiveness of CLDN6 CAR-T cells, both with and without the CLDN6 RNA-LPX vaccine[1].

The main objectives of the trial are:

  1. To assess the safety and tolerability of the treatment.
  2. To evaluate how well the treatment works in fighting cancer.
  3. To study the immune response triggered by the treatment[1].

Who is eligible for the trial?

The trial is open to adults (18 years or older) with advanced solid tumors that express the CLDN6 protein. Some key eligibility criteria include:

  • Having a CLDN6-positive tumor, as determined by a specific laboratory test.
  • Having adequate blood cell counts and liver and kidney function.
  • Having a cancer that has spread or cannot be surgically removed, and for which standard treatments are not available or not suitable.
  • Being able to attend all required trial visits[1].

There are also several factors that might exclude someone from participating, such as having received certain previous treatments or having specific medical conditions. It’s important to discuss eligibility with a healthcare provider.

Safety and Effectiveness

As RBP030.2 is still in early-stage clinical trials, its full safety profile and effectiveness are not yet known. The current trial is designed to gather this important information. Researchers will be closely monitoring for any side effects, particularly those that might be severe or serious[1].

The trial will also assess how well the treatment works against cancer. This will be measured by looking at factors such as:

  • The proportion of patients whose tumors shrink or disappear (objective response rate).
  • How long the treatment effect lasts (duration of response).
  • Changes in immune system activity[1].

It’s important to remember that as an experimental treatment, RBP030.2 may have unknown risks and its effectiveness is not yet proven. Patients considering participating in the clinical trial should discuss the potential risks and benefits thoroughly with their healthcare team.

Aspect Details
Drug Name RBP030.2 (BNT211)
Trial Phase Phase I/IIa
Target Conditions Advanced solid tumors, including malignant solid tumors, carcinoma of unknown primary, testicular cancer, and non-small cell lung cancer
Mechanism CLDN6 CAR-T cell therapy with or without CLDN6 RNA-LPX vaccine
Main Objectives Assess safety, tolerability, and preliminary efficacy
Key Eligibility Criteria CLDN6-positive tumor, ≥18 years old, no available standard therapy
Primary Endpoints Treatment-emergent adverse events, dose-limiting toxicity
Secondary Endpoints Changes in immune factors, objective response rate, duration of response

FAQ

  • What is RBP030.2 and how does it work? RBP030.2 is an investigational drug that uses a special type of cell therapy called CLDN6 CAR-T. It works by modifying a patient's own immune cells to target and fight cancer cells that have a specific protein called CLDN6 on their surface.
  • What types of cancer is RBP030.2 being tested for? RBP030.2 is being tested for various advanced solid tumors, including malignant solid tumors, carcinoma of unknown primary, testicular cancer, and non-small cell lung cancer. It's designed for patients whose cancer has spread or cannot be removed surgically.
  • Who is eligible to participate in the clinical trial for RBP030.2? Eligible participants must be at least 18 years old, have a CLDN6-positive tumor, and have no available standard therapy that is likely to help them. They must also meet specific health criteria and be willing to follow the trial's requirements.
  • What are the main goals of the clinical trial for RBP030.2? The main goals of the trial are to assess the safety and tolerability of RBP030.2, evaluate its effectiveness in fighting tumors, and study how it affects the immune system. The researchers also want to determine the best dose for future treatments.
  • Are there any potential side effects of RBP030.2? As with any experimental treatment, there may be side effects. The trial is designed to carefully monitor participants for any adverse events, including serious side effects. Specific information about potential side effects will be gathered during the study.

Ongoing Clinical Trials on Rbp030.2

  • A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany The Netherlands Sweden

Glossary

  • CLDN6 CAR-T: A type of cell therapy where a patient's T cells (immune cells) are modified to express a receptor that targets CLDN6, a protein found on some cancer cells.
  • RNA-LPX: A vaccine made of RNA (genetic material) enclosed in tiny fat bubbles called liposomes. It's designed to help the immune system recognize and fight cancer cells.
  • Solid tumor: A mass of abnormal cells that doesn't contain liquid or cysts. Examples include tumors in the lungs, breast, or colon.
  • Metastatic: Cancer that has spread from its original location to other parts of the body.
  • Unresectable: A tumor that cannot be removed completely through surgery.
  • Immunohistochemistry (IHC): A lab test that uses antibodies to detect specific proteins in tissue samples, helping to diagnose certain types of cancer.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, version 1.1. A standard way to measure how well a cancer patient responds to treatment.
  • Dose-limiting toxicity (DLT): Side effects of a treatment that are severe enough to prevent increasing the dose or continuing the treatment.
  • Objective response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Duration of response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-cldn6-car-t-and-cldn6-rna-lpx-in-patients-with-advanced-solid-tumors/